



AD-A286 653



**R
E
P
O
R
T**

**NINTH
ANNUAL
CONFERENCE
ON HUMAN
RETROVIRUS
TESTING**

This document has been approved
for public release and sale; its
distribution is unlimited.

**Reno, Nevada
March 1994**

94-35465

94 11 16 07 5

DTIC QUALITY INSPECTED 8

AD _____

GRANT NO: DAMD17-94-J-4018

TITLE: 9th Annual Conference on Human Retrovirus Testing

PRINCIPAL INVESTIGATOR: Jerome R. Cordts

CONTRACTING ORGANIZATION: ASTPHLD

REPORT DATE: March 2-4, 1994

TYPE OF REPORT: Published Proceeding

PREPARED FOR: U.S. Army Medical Research and Materiel
Command Fort Detrick,
Frederick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Accession For	
NTIS CRA&I	☒
DTIC TAB	☐
Unannounced	☐
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A-1	

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 3/2-4/94		3. REPORT TYPE AND DATES COVERED Conference Proceedings	
4. TITLE AND SUBTITLE 9th Annual Conference on Human Retrovirus Testing				5. FUNDING NUMBERS DAMD17-94-J-4018	
6. AUTHOR(S) ASTPHLD (Jerome R. Cordts)					
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) ASTPHLD 1211 Connecticut Avenue, NW, Suite 608 Washington, D.C. 20036				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Frederick, MD 21702-5012				10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES					
12a. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release; distribution unlimited				12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) see proceedings					
14. SUBJECT TERMS Human Retrovirus Testing				15. NUMBER OF PAGES 30	
				16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unclassified		

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

James R. Caff 10/6/94
PI - Signature Date

**R
E
P
O
R
T** **NINTH
ANNUAL
CONFERENCE
ON HUMAN
RETROVIRUS
TESTING**

**Reno, Nevada
March 1994**

TABLE OF CONTENTS

Conference Summary	1
Plenary Session Speakers	3
Issues Forum:	
Testing: HIV-1 and HIV-2 Algorithms	5
Issues Forum:	
Non-Traditional HIV Testing	7
Issues Forum:	
Western Blot False Positives and Issues of Testing in the era of vaccines	9
Round Table	
International Perspectives	11
Abstracts	13
Index to Abstract Authors.	17
Conference Attendees.	21

CONFERENCE SUMMARY

The Ninth Annual Conference on Human Retrovirus Testing, held in Reno, Nevada on March 2-4, 1994 advertised the following purpose. "A forum on national and international laboratory-related retroviral issues which will allow for an exchange of information and ideas and encourage discussion of current issues". Judging from the presentations delivered during the plenary sessions and issues forums and the discussions they evoked both in the sessions, at the evening breakouts and in the halls, the purpose of the conference was met.

The conference was sponsored by the Association of State and Territorial Public Health Laboratory Directors. As in previous conferences, the Ninth Conference addressed many of the issues associated with retrovirus testing and again served as a vehicle for the disseminations of attendees' concepts and views germane to human retrovirus testing. Over three hundred participants attended the three day conference. Fifty poster sessions were presented and 14 exhibitors presented products related to HIV testing.

Mr. Charles Schable, Chief of the Serology Section, CDC, presented a well attended session on "The Basics of Retroviral Testing: the evening before the main conference program. The session gave participants an opportunity to brush up on their knowledge of retroviral testing and set the stage for the conference program over the next two days.

The first plenary session addressed the status of human retrovirus testing and covered pediatric AIDS, alternative CD4 technologies, current issues of HTLV testing and an international perspective on HIV testing. AIDS is of global concern and the international perspective on HIV testing presented by Dr. Ofelia Monzon was enlightening.

The issues forum on Wednesday continued the on going discussion of algorithms. This conference report contains a summary of the discussion and conclusions reached. On Thursday non-traditional HIV testing was the subject of Issues Forum II. Non-traditional testing continues to be controversial with the introduction of home testing. Regulatory affairs were covered in the Wednesday afternoon issues forum. Discussion on regulatory issues have a way of evoking strong opinions and this meeting was no exception. The fourth issues forum was on Western Blot False Positive and Issues of Testing in the Era of Vaccines. West blot false interpretation and the problems associated with the testing methodology continue to be a challenge. The forum attempted to address the problems associated with this testing and the problems that vaccines are presenting. A position paper derived from the session is included in this report.

The conference was concluded by the second plenary session. The session addressed systemic lymphoid response in early HIV infection, new horizons in molecular testing of HIV and a report on ASTPHLD's international training efforts.

PLEASE NOTE:

This conference did not address issues previously address in the first eight Conferences on Human Retrovirus Testing. Proceedings from those conferences may be obtained from: ASTPHLD, 1211 Connecticut Avenue, N.W., Suite 608, Washington, D.C. 20036

PLENARY SESSION SPEAKERS

Pediatric AIDS: correlates of Perinatal Transmission and Strategies for Interruption

Diane Wara, M.D.

Alternative CD₄ Technologies

Janet Nicholson, Ph.D.

The HTLVs: Current Issues

Jonathan Kaplan, Ph.D.

HIV Testing - An International Perspective

Ofelia Monzón, M.D.

Systemic Lymphoid Response in early HIV Infection

Ronald Turnicky, D.O., LTC, MC

New Horizons in Molecular Diagnostics

Helen Lee, Ph.D.

ASTPHLD International Training

David Carpenter, Ph.D.

ISSUES FORUM: TESTING: HIV-1 AND HIV-2 ALGORITHMS

PANEL MODERATOR:

Jane Getchell, Dr.P.H., Associate Director, State Hygienic Laboratory, University of Iowa, Iowa City, Iowa

PANEL MEMBERS:

Barbara Werner, Ph.D., Director, Virology / Clinical Investigation Division, Massachusetts State Laboratory Institute, Jamaica Plain, Massachusetts

Robert Myers, Ph.D., Laboratory Scientist, Maryland Department of Health, Baltimore, Maryland

William Schalla, M.S., Chief, Model Performance Evaluation Program, Centers for Disease Control and Prevention, Atlanta, Georgia

Charles Schabel, M.S., Chief, Serology Section, Division of HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia

Hermann A.M. Mücke, Ph.D., Senior Vice President of Research and Development, Waldheim Pharmazeutika R&D Laboratory, Austria

In the U.S. all HIV testing algorithms consist of a screening test followed by a confirmatory test. Beyond this, no single sequence of testing is common to all laboratories. The specific algorithm used depends on the prevalence of infection in the population, the resources available to the laboratory, the volume of testing, the desired turnaround time, etc. IFA and WB are acceptable confirmatory tests. For any first time positive report on an individual, a request should be made to submit another sample for repeat testing. Tests used in resolving inconclusive confirmatory test results include antigen assays, recombinant and synthetic based assays, and PCR.

Testing for HIV-2 as part of the screening process results in a greater number of specimens requiring supplemental testing, few of which are actually confirmed as HIV-2. Screening for HIV-1 alone detects 60 to 90% of HIV-2 infections. As of March 1994, 49 cases of HIV-2 infection have been reported in the U.S. from 13 states. States that have tested specimens giving atypical HIV-1 WB patterns (gag and pol bands only) with HIV-2 specific assays have successfully identified HIV-2 infection.

ISSUES FORUM NON-TRADITIONAL TESTING

PANEL MODERATOR:

Charles Schable, M.S., Chief, Serology Section, Division of HIV/Aids, Centers for Disease Control and Prevention, Atlanta, Georgia

PANEL MEMBERS:

J. Richard George, Ph.D., Chief, Developmental Technology Division, Division of HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia

Ms. Cynthia Cossen, Supervising Microbiologist, VRDL, CA Dept. of Health, Berkeley, CA

William Kassler, Ph.D., National Center for Prevention Services, Centers for Disease Control and Prevention, Atlanta, Georgia

Wanda Jones, Dr. P.H., Assistant Director for Science, Office of HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, Georgia

The use of non-traditional specimens such as dried blood spots or saliva have been shown to be technically feasible. Research assays using EIA or WB specifically designed for, or modified for such specimens are clearly concordant with the standard serum testing algorithms. Unfortunately, licensed confirmatory procedures are currently not available and are an impediment to the routine use of non-traditional specimens. Hopefully this issue will resolve itself in the future as these products become licensed.

The use of rapid (<15 min) assays to detect HIV antibody in the clinic-based setting have yet to be proven themselves. Conflicting data exist as to whether clients will wait for their results from these rapid tests. ASTPHLD restates the position that persons should not be informed of a positive result unless it was confirmed by a more specific test such as WB or IFA.

There are several companies working with health departments and CDC to refine home sample collection devices. These are NOT home testing kits, but devices in which a specimen will be collected at home, mailed to a reference lab, and the client will then call at a later date for their result. On-going surveys suggest that these collection devices are technically feasible. However, since counseling is an integral part of HIV testing, the actual benefits of these devices is unproven.

ISSUES FORUM WESTERN BLOT FALSE POSITIVE AND ISSUES OF TESTING IN THE ERA OF VACCINES

PANEL MODERATOR:

Michael Ascher, M.D., Chief, AIDS Support, VDRL, California Department of Health Services, Berkeley, California

PANEL MEMBERS:

J. Richard George, Ph.D., Research Microbiologist, Centers for Disease Control and Prevention, Atlanta, Georgia

Haynes W. Sheppard, Ph.D., Research Scientist, VRDL, California Department of Health Services, Berkeley, California

Keith Sayre, M.S., Product Manager, Ortho Diagnostics, Raritan, New Jersey

In the continuing evolution of screening tests for HIV capable of narrowing the "window period" and detecting the HIV-2 variant, problems with nonspecificity of the EIA assays have occurred. The false-positive samples arising from this situation are samples that come from uninfected individuals but which test positive on one or more screening assays and have a positive confirmatory test result. The Western blot patterns are incomplete suggesting seroconversion consisting of either envelope-only reactions at the regions of gp41, gp120 and gp160, or the coincidence of such envelope band(s) with the occurrence of a false positive gag reaction, typically at p24. These samples contain no other bands and they fail to progress over time to a more complete pattern of bands on Western blot. Some of these samples are also positive on IFA. A positive antigen test can be useful in resolving such samples. Recombinant and sythetic peptide EIA tests give variable reactivity on these samples. A negative result using either test on an apparent seroconverter should be a "red flag" for further studies.

These samples first began to be described with the 1990 enhancement of EIA tests and have increased further with the use of newer generation combi HIV 1 2 tests.

Current recommendations establish that failure to progress at six months is definitive for lack of HIV infection. However, in most cases, the resolution of such samples can be made by examining a followup sample for progression of band pattern at a one to three month interval.

It is therefore recommended that all samples having the appearance of a minimal seroconversion on blot (with no other bands) can be reported as positive but that the written result should include a note that such results can be nonspecific and that a followup sample is recommended to establish progression to a more complete pattern. The time limit for defining absence of infection should be stated.

Samples from those who have participated in HIV vaccine trials may give unusual patterns, resulting in erroneous interpretations. Studies to differentiate such specimens from true positives are in progress.

ROUND TABLE: INTERNATIONAL PERSPECTIVES

MODERATOR:

William J. Hausler, Jr., Ph.D., Director, University Hygienic Laboratory, University of Iowa.

PANEL MEMBERS:

Elizabeth M. Dax, M.D., National HIV Reference Laboratory, Australia

Ofelia Monzón, M.D., Consultant, ADS Research Group, Research Institute for Tropical Medicine, Manila, Philippines.

The fundamental purpose was to discuss ways in which the ASTPHLD could provide its assistance or presence in the international sphere of retrovirus testing.

Discussants made it very clear that the early consensus conferences did much to establish international recognition of standards of laboratory performance and reporting. Problems cited were inability to replicate USA laboratory environments, personnel, acquisition of reagents and specimen transport. In addition, many countries do not have sufficient regulations in force to prevent import and sale of reagents near or just beyond expiration date.

Countries outside the USA are not so much in need of training for relatively simple retrovirus laboratory diagnostic techniques as they are for assistance in guiding them to develop their own operational standards based on indigenous problems not encountered in the USA. The ASTPHLD was encouraged to become more active in assisting countries in the laboratory testing standardization process now that the WHO has significantly reduced its laboratory component.

The program committee is challenged to provide an international activities section within each Conference on Human Retrovirus Testing where laboratory scientists, manufacturers and program managers can meet and discuss issues of direct concern in human retrovirus testing in non-USA areas. The epidemic of HIV infection continues to expand and the ASTPHLD needs to maintain its public health laboratory leadership role.

ABSTRACTS

(Abstracts were reproduced in the conference program)

- 1 **Multisite Evaluation of the Murex SUDS® HIV-I Test for Detection of Antibody to Human Immunodeficiency Virus Type 1,** Richard C. Alexander, Dennis Ferrero, Bruce Fujikawa.
- 2 **HIV Study comparing the ability of serum, urine and saliva to Detect HIV seropositivity in known HIV-1 positive individuals,** M.A. Wilke, M.A. Baker, L.M. McIntosh, L.M. Killingsworth, L.R. Bernard.
- 3 **Does contact between Dried Blood Spots transfer HIV Seropositivity?** Carol J. Bell, Trudy L. Dobbs, and W. Harry Hannon.
- 4 **Comparative Performance of a Synthetic Peptide Assay as a Supplemental Test for HIV Antibody Detection,** S.B. Bennett, S. Fordan, S. Lampp, E.E. Buff, E.C. Hartwig, D. Frazier.
- 5 **Detection of HIV-1 Proviral DNA in Patient Samples Using a Novel Single-Temperature Amplification,** T.B. Ryder, E.R. Billyard, D.K. Cabanas, F. Garduno, T. Lawrence, K. Nunomura, G. Schneider, T. Smith, K. Ueding.
- 6 **A Microparticle Enzyme Immunoassay for the detection of antibodies to HIV-1 and HIV-2 on a Random Access Automated Analyzer,** W. Black, G. Hall-Steele, S. Stewart, S. Kramer, B. Sehgal, D. Daghfal
- 7 **Inter-shipment Reproducibility of HIV-1 Western Blot (WB) Results Reported in Five Paired Shipment Periods by Laboratories in a Model Performance Evaluation Program,** Sharon O. Blumer, James H. Handsfield, William O. Schalla.
8. **TRAX™ CD8 Test Kit: A Simple Alternative to Flow Cytometry for the Enumeration of CD8 Positive T Cells,** Susan Carrabis, Greg Litwak and Kim Foster.
- 9 **Use of a Rapid HIV-1 Screening Test to improve client return rates,** R. Rockwell, C. Cossen, R. Alexander, D. Ferrero, B. Fujikawa.
- 10 **Evaluation of Laboratory Performance of T-Lymphocyte Immunophenotyping (TLI) in Support of HIV-1 Infected Patient Care and Management,** C.D. Cross, W.O. Schalla, R.N. Taylor, J.H. Handsfield.

- 11 **Sensitivity Comparison of an Antigen Conjugate EIA (Abbott List 3A77) with an Indirect EIA (Abbott List 3A11): Correlation with the PResence of Anti-p41 Antibody in HIV-1 Indeterminate Samples as Determined by a Recombinant Dot Blot Assay (Abbott Matrix HIV-1/HIV-2),** M.B. Peterson, K.M. Knigge, R.L. Falcon, C.K. Daluga, C.A. Skora, J.L. Gallarda, K.M. Knigge, B.L. Daanen.
- 12 **In-field Assay Specificity of Anti-HIV-1/HIV-2 EIAs in Australian Blood Banks,** Marisa Bendistinto, Thomas A. Vandebelt, Elizabeth Dax.
- 13 **Universal Donor Screening for HTLV in Australia: A review of testing results,** Elizabeth A. Dax, Colin Silvester, Marisa Bendistinto, Anna Karopoulos, Thanh Ha Huynh, Marina Karakaltsas, Fiona Rae, Susan J. Best, David S. Healey, Thomas A. Vandebelt, Jeff Clancy.
- 14 **HIV-1 Western Blot compared with Enzyme Immunoassay in HIV-1 Seroconversion,** Thanh Ha Huynh, David S. Healey, Colin Silvester, Elizabeth M. Dax.
- 15 **An Assessment of New York State's Experience as an HIV-1 Referral Testing Laboratory: Suggestions and Considerations,** C. Flood, M. Neal, J. Wethers.
- 16 **Blind Proficiency Studies for T-Lymphocyte Immunophenotyping,** D.P. Francis, K.M. Peddecord, A.S. Benenson, L.K. Hofherr, J. Rau, Q. Xie, D.B. Scharf, G.D. Cross, W.O. Schalla.
- 17 **Report Content of HIV-1 Antibody Testing Results,** A.S. Benenson, K.M. Peddecord, L.K. Hofherr, D.P. Francis, R.S. Garfein, J. Rau, Q. Xie, D.B. Scharf, R.N. Taylor, W.O. Schalla, R.E. Safrin, N.A. Dewan.
- 18 **Comparison of sensitivity of Two New Commercial Enzyme Immunoassays for the Detection of HTLV-1 and HTLV-11 Antibody,** Dana Gallo, Shideh Kashe, Marjorie Hoffman.
- 19 **Algorithms for HIV Testing - Experience in a Canadian Laboratory,** Rick Galli, Carol Major, Margaret Fearon, Michael Montpetit, Debbie Lepine.
- 20 **Delineation of an Immunodominant and highly HTLV specific epitope within HTLV-1 Transmembrane Glycoprotein,** Kenneth G. Hadlock, Chin-Joo Goh, Peggy A. Bradshaw, Susan Perkins, Rima Khabbaz, Jonathan Lo, Steven K.H. Fong.
- 21 **Possible False Positivity with HIV-1 envelope only reactivity on Western Blot identified through detection of plasma RNA,** Denis R. Henrard, Jack Phillips, Christine V. Sapan, Lynne Layug, Roger Dodd.
- 22 **Detection of HIV-2 Antibodies in Saliva,** Lindsay Hofman, Lebah Lugalia and Chyang Fang.
- 23 **Performance Evaluation of a Synthetic Peptide-Based Screening EIA for HTLV-I and II Antibodies,** Barbara Hosein, Alan Walfield, John Ye, Rosanne Boyle.

- 24 **Comparison of Licensed HIV 1/2 combination EIA's for early detection of HIV-1 Antibodies**, Pamela Markwardt-Elmer, Lisa Hughes, and Joan Pfister.
- 25 **Base Dissociation Assay (BDA) for Immune-Complex Dissociation (ICD) and Detection of HIV-I p24 compared with three commercial ICD Kits**, J.M. Hyman, D.E. Lockwood, T.J. Holody, P. Youngbar.
- 26 **Performance of an immunoassay for simultaneous detection of antibodies to HTLV-I and HTLV-II**, Joan Johnson, Emerson Chan, Mark Buytendorp, Cheryl Motley, Eugene Robertson, John Stephens, Bruce Phelps.
- 27 **Modeling Use of a Rapid Test for HIV Infection: Potential Costs and Effects**, Jones, W.K., Famham, P.G., Gorsky, R.D., Holtgrave, D.R.
- 28 **The Performance of a rapid HIV assay in public clinics**, William J. Kassler, Charles Haley, Wanda K. Jones, A. Russell Gerber, Edward Kennedy, J. Richard George, Timothy Granade, Barry Mitchell.
- 29 **HIV-I ELISA System Enhancements to improve specificity; Performance of OTC's Vironostika HIV-1 Microelisa System (VirHIV-1) (Cat. #59600 Series) in Sera/ Plasma Specimen Populations**, Kay, J.W.D., Jones, G.R., and Witt, D.
- 30 **HIV-I ELISA System Enhancements to Improve specificity; Performance of OTC's Vironostika HIV-I Microelisa System (VirHIV-1) (Cat. #59600 Series) in Dried Blood Spot (DBS) Specimen Populations**, Kay, J.W.D., Jones, G.R., Witt, D.
- 31 **Evaluation of apoptosis in monitoring immune status in neonatal HIV infection**, La Via, M.F., Del Llano, A.M., Johnson, G.M., Perrella, O., Paulling, E., Laverne, J.A.
- 32 **Evaluation of an Indirect Immunofluorescence Assay (Fluorognost HIV-2 IFA) for the detection of HIV-2 Antibodies**, S. Lee-Thomas, C.P. Pau, H. Mucke, M. Schinkinger, J.R. George.
- 33 **Development of a Highly Sensitive and Specific HIV-1/2 EIA using any and po Synthetic Peptides**, N. Monji, C.A. Cole, D. Mercier, J. Montana, P. Shores, P.C. Su, L. Williams and P. Coleman.
- 34 **Quantification of an HIV-I Antibody IFA by Single-Cell Scanning Photometry**, Hermann A.M. Mucke, Manfred Schinkinger.
- 35 **An Evaluation of an Indirect Immunofluorescence Assay (IFA) for confirmation of HIV-I Antibody in Adult Sera and in Eluates of Dried Blood Spots**, Neal, M., Wethers, J.
- 36 **Evaluation of MicroTrak® II HIV-1/HIV-2 Recombinant EIA**, S. Phillips, T. Granade, J.R. George.
- 37 **Improved Detection of HIV Antigen Following Alkaline Dissociation of Immune Complexes**, M. Ramirez, N. Swack, S. Berberich, J. Stapleton.

- 38 **Comparison of Three Sets of Western Blot Interpretive Criteria: (Data from the National HIV Seroprevalence Surveys),** Martha A. Redus, Catherine L. Spruill, Marta Gwinn, Susan Davis, Charles Schable, J. R. George.
- 39 **HIV-1/HIV-2 Recombinant/Peptide EIA: The Next Generation,** C. Skora, B. Daanen, C. Daluga, B. Falcon, M.B. Peterson, J. Gallarda.
- 40 **Detection of HTLV-I and HTLV-II Antibodies by HTLV-I Assays: A Comparison of Eight Assays,** B.J. Weiblen, R.T. Schumacher, S.R. Delaney, V. Rieckenberg, S.L. Stramer, H. Kiyokawa.
- 41 **TRAX™ CD4: An alternative Method to Flow Cytometry for CD4+ Cell Enumeration Eases Sample Handling Restrictions,** Ellen Urquhart, Anthony Pulsone, Monique Morimoto.
- 42 **A Testing Algorithm for HTLV-I/II derived from a case definition approach to data Interpretation,** J.E. Valinsky, M. Rios, C. Bianco.
- 43 **Effects of Conversion to HIV-1/HIV-2 EIA Screening on donor re-entry.** D. Strauss, J.E. Valinsky, D. Kessler, C. Bianco.
- 44 **Signal Amplification Technique (ELAST) improves detection of HIV p24 Antigen in early seroconversion,** B. Weiblen, L. Durgin, P.E. Garrett, R. Schumacher, M. Cody.
- 45 **Determination of Lymphocyte Subsets by a New Alternative Technology,** Thomas N. Denny, Bruce Jensen, Ambrosia Garcia, Frank Vella, Edie Gavin, James Oleske, William Wong.
- 46 **Effects of Temperature, Time, and Plasma Separation on Quantitative Plasma HIV-1 RNA Levels,** B. Yen-Lieberman, J.T. Carey, C. Starkey, T.G. Spahlinger, C.L. Reinhardt, and J.B. Jackson.
- 47 **Comparison of Surrogate Markers and HIV-1 RNA Levels in Patients with Advanced HIV Infection,** C.A. Starkey, S.J. Rehm, J.K. Pohlman, B. Yen - Lieberman.
- 48 **Performance Characteristics of HIV-2 Serology Reagents on Blood from SIV/HIV-2 Infected Primates,** JoAnn L. Yee, Myra B. Jennings, Linda J. Lowenstein, Nicholas W. Lerche, James R. Carlson.
- 49 **Screening a Low Prevalance Population for HIV-2 using a Combination HIV-1/HIV-2 Enzyme Immunoassay and an Immunofluorescent Assay,** S.N. Zanto, L.J. Treichel, D.O. Abbott.
- 50 **The FACSCOUNT™ System: Evaluation of an Alternative Technology for Absolute CD4 Counts,** A. Shiba, J.K. Nicholson, W. Velleca, K. Webster.

INDEX TO ABSTRACT AUTHORS

Abbott, D.O.	49	Cody, M.. . . .	44
Alexander, R.C.	1, 9	Cole, C.A.	33
Baker, M.A.	2	Coleman, P.	33
Bell, C.J..	3	Cossen, C.	9
Bendistinto, M.	12, 13	Cross, G.D.	10, 16
Benenson, A.S.	16, 17	Daanen, B.L.	11, 39
Bennett, S.B.	4	Daluga, C.K.	11, 39
Berberich, S.	37	Daghfal, D.	6
Bernard, L.R.	2	Davis, S.. . . .	38
Best, S.J.	13	Dax, E.	12, 13, 14
Bianco, C.	42, 43	Denny, T.N.	45
Billyard, E.R.	5	Delaney, S.R.	40
Black, W.	6	Del Llano, A.M.	31
Blumer, S.O..	7	Dewan, N.A.. . . .	17
Boyle, R.. . . .	23	Dobbs, T.L.	3
Bradshaw, P.A.	20	Dodd, R.. . . .	21
Buff, E.E.	4	Durgin, L.	44
Buytendorp, M.	26	Falcon, M.B.. . . .	39
Cabanas, D.K.	5	Falcon, R.L.	11
Carey, J.T.. . . .	46	Fang, C.	22
Carlson, J.R.	48	Farnham, P.G.. . . .	27
Carrabis. S.	8	Fearon, M.. . . .	19
Chan, E.. . . .	26	Ferrero, D.. . . .	1, 9
Clancy, J.	13	Flood, C.	15

Foster, K.	8	Hofherr, J.	16, 17
Fordan, S.	4	Hoffman, M.	18
Foung, S.K.H.	20	Hofman, L.	22
Francis, D.P.	16, 17	Holtgrave, D.R.	27
Frazier.	4	Holody, T.J.	25
Fujikawa, B.	1, 9	Hosein, B.	23
Galli, R.	19	Hughes, L.	24
Gallo, D.	18	Huynh, T.H.	13, 14
Gallarda, J.L.	11, 39	Hyman, J.M.	25
Garcia, A.	45	Jackson, J.B.	46
Garduno, F.	5	Jennings, M.B.	48
Garfein, R.S.	17	Jensen, B.	45
Garrett, P.E.	44	Johnson, G.M.	31
Gavin, E.	45	Johnson, J.	26
George, J.R.	28, 32, 36, 38	Jones, G.R.	29, 30
Gerber, A.R.	28	Jones, W.K.	27, 28
Goh, C-J.	20	Karakaltsas, M.	13
Gorsky, R.D.	27	Karopoulos, A.	13
Granade, T.	28, 36	Kashe, S.	18
Gwinn, M.	38	Kassler, W.J.	28
Hadlock, K.G.	20	Kay, J.W.D.	29, 30
Haley, C.	28	Kennedy, E.	28
Hall-Steele, G.	6	Kessler, D.	43
Handsfield, J.H.	7, 10	Khabbaz, R.	20
Hannon, W.H.	3	Kinningsworth, L.M.	2
Hartwig, E.C.	4	Kiyokawa, H.	40
Healey, D.S.	13, 14	Knigge, K.M.	11
Henrard, D.R.	21	Kramer, B.	6

Lampp, S.	4	Pau, H.	32
Lavergne, J.A.	31	Paulling, E.	31
La Via, M.F.	31	Peddecord, K.M.	16, 17
Lawrence, T.	5	Perella, O.	31
Layug, L.	21	Perkins, S.	20
Lee-Thomas, S.	32	Peterson, M.B.	11, 39
Lepine, D.	19	Pfister, J.	24
Lerche, N.W.	48	Phelps, B.	26
Litwak, G.	8	Phillips, J.	21
Lo, J.	20	Phillips, S.	36
Lockwood, D.E.	25	Pohlman, J.K.	47
Lowenstine, L.J.	48	Pulsone, A.	41
Lugalia, L.	22	Rae, F.	13
Major, C.	19	Ramirez, M.	37
Markwardt-Elmer, P.	24	Rau, J.	16, 17
McIntosh, L.M.	2	Redus, M.	38
Mercier, D.	33	Rehm, S.J.	47
Mitchell, B.	28	Reinhardt, C.L.	46
Monji, N.	33	Rieckenberg, V.	40
Montpetit, M.	19	Rios, M.	42
Montana, J.	33	Robertson, E.	26
Morimoto, M.	41	Rockwell, R.	9
Motley, C.	26	Ryder, T.B.	5
Mücke, H.	32, 34	Safrin, R.E.	17
Neal, M.	15, 35	Sapan, C.V.	21
Nicholson, J.K.	50	Schable, C.	38
Nunomura, K.	5	Scharf, D.B.	16, 17
Oleske, J.	45	Schalla, W.O.	7, 10, 16, 17

Schinking, M.	32, 34	Webster, K.	50
Schneider, G.	5	Weiblein, B.	44
Schumacher, R.T.	40, 44	Wethers, J.	15, 35
Sehgal, B.	6	Williams, L.	33
Sh.	50	Wilke, M.A.	2
as, P.	33	Witt, D.	29, 30
St.	13, 14	Wong, W.	45
Skora, C.A.	11, 39	Xie, Q.	16, 17
Smith, T.	5	Ye, John.	23
Spahlinger, T.G.	46	Yee, JoAnne.	48
Spruill, C.L.	38	Yen-Lieberman, B.	46, 47
Stapleton, J.	37	Youngbar, P.R.	25
Starkey, C.A.	46, 47	Zanto, S.N.	49
Stephens, J.	26		
Stewart, S.	6		
Stramer, S.L.	40		
Strauss, D.	43		
Su, P.C.	33		
Swack, N.	37		
Taylor, R.N.	10, 17		
Treichel, L.J.	49		
Ueding, K.	5		
Urquhart, E.	41		
Valinsky, J.E.	42, 43		
Vandenbelt, T.A.	12, 13		
Vella, F.	45		
Velleca, W.	50		
Walfield, A.	23		

CONFERENCE ATTENDEES

Sandra Aarnaes

Supervisor, Microbiology, University of CA, Irvine Medical Center, Rt. 19, 101 City Drive, Orange, CA 92668

Al Absher

Organon Teknika, 100 Akzo Avenue, Durham, NC 27712

Richard C. Alexander

Laboratory Director, San Bernardino County, Public Health Department, 799 E. Rialto Avenue, San Bernardino, CA 92415-0011

Thomas S. Alexander Ph.D.

Immunologist, Summa Health System, 525 E. Market Street, Dept. of Pathology, Akron, OH 44309-2090

Kim Anderson

HIV Lead Tech, Osborn Laboratories, 14901 W. 117th St., Olathe, KS 66062

Michael Ascher M.D.

Deputy Chief, Viral and Rickettsial Disease Lab, California Dept. of Health Services, 2151 Berkeley Way, Berkeley, CA 94704

Farah Babakhani

Branch Supervisor, Medical Serology, Texas Department of Health, 1100 West 49th Street, Austin, Texas

Mary Beth Baker

Virology Supervisor, Pathology Associates Medical Laboratories, E. 11604 Indiana, Spokane, WA 99206

Lawrence A. Baker

Research Manager, CIBA-Corning Diagnostics, 333 Coney St., E. Walpole, MA 02032-1597

Elizabeth Baylis

Virologist, Public Health Foundation, California, 2151 Berkeley Way, Berkeley, CA 94801

Carol J. Bell

Project Administrator, ISQAL, Centers for Disease Control/Prevention, 4770 Buford Highway NE (MS-F19), Chamblee, GA 30341-3724

Spencer B. Bennett

Retrovirology Supervisor, Florida HRS Office of Lab Services, 1217 Pearl St., Jacksonville, FL 32202

Christopher Bentsen

Director-Regulatory, Quality and Clinical Affairs, Genetic Systems / Sanofi Diagnostics Pasteur, 6565 185th Avenue, N.E., Redmond, WA 98052

Richard Berman

Director Clinical Microbiology, Pennsylvania State Public Health Lab., P.O. Box 500, Exton, PA 19341-0500

Beth Billyard

Research Scientist, Gen-Probe, 9880 Campus Point Drive, San Diego, CA 92121

William Black

R & D Project Manager, Abbott Laboratories, One Abbott Park Road, Abbott Park, IL 60064

James W. Blaine Ph.D.

Assistance Bureau Director, Virginia Consolidated Laboratory Services, One North 14th Street, Richmond, VA 23219

Sharon Blumer M.S.

Centers for Disease Control and Prevention, 4770 Buford Hwy, NE Mailstop, Atlanta, GA 30341

John A. Boffa

Vice President, Technical Service GIB Laboratory, 41 Spring Street, New Providence, NJ 07974

Robin Botchlet

Supervisor Immunology, Public Health Laboratory, Oklahoma State Dept of Health, P.O. Box 24106, Okla City, OK 73124-0106

Richard M. Braun
*Boston Biomedica, Inc., 375 W. Street, W.
Bridgewater, MA 02379*

Timothy J. Brosz
*Microbiologist, ND State of Dept. of Health &
Consolidated Laboratories, 1205 Ave. A West,
P.O. Box 5520, Bismarck, ND 58502-5520*

Dr. Arthur Brown
*Walter Reed Army Institute of Research, 13 Taft
Court, Suite 201, Rockville, MD 20850*

Mark A. Cannon
*Laboratory Manager, U.S. Army, 13 Taft Court
Suite 201, Rockville, MD 20850*

David F. Carpenter Ph.D.
*Director, Division of Laboratories, IL Department
of Public Health, 825 N. Rutledge, P.O. Box
19435, Springfield, IL 62794*

Julie Ann Chalmers
*Medical Technologist, Immunology Lab Univer-
sity Hospital, University of Virginia, Charlottes-
ville, VA 22908*

Jerome R. Cordts, M.Ed.
*Executive Director, ASTPHLD, 1211 Connecticut
Avenue, N.W., Suite 608, Washington, D.C.
20036*

Coleman Chuen
*Abbott Diagnostics, Dept. 2TN/AP6C, Abbott
Park, IL 60064*

Gabrielle Cloutier
*Lab Technologist, Blood Center of S.E. Wiscon-
sin, 626 S. 66th Street, Milwaukee, WI 53214*

Patrick F. Coleman M.D.
*Director, R&D, Genetic Systems, 6565 185th
Ave., N.E., Redmond, WA 98052*

Greg Coleman
*Sanofi Diagnostics Pasteur, 1000 Lake Hazeltine
Drive, Chaska, MN 55318*

Jeanne Connelly
*Product Mgr., Worldwide Commercial Develop-
ment, Ortho Diagnostics Systems, Inc., 1001 US
Hwy 202, P.O. Box 350, Raritan, NJ 08869-0606*

James M. Conroy
*Research Scientist, New York State Department
of Health, 120 New Scotland Avenue, David
Axelrod Institute, Albany, NY 12201-2002*

Dr. Niel T. Constantine Ph.D.
*Director, Clinical Immunology, Univ. of Maryland,
N2W65, 22 S. Greene St., Baltimore, MD 21201*

Cynthia Cossen
*Public Health Microbiologist, Viral & Rickettsial
Disease Lab., California Public Health Labora-
tory, 2151 Berkeley Way, Berkeley, CA 94704*

Rodger Counderson
Coulter Corporation, P.O. Box 169015, Miami, FL

Chuck Crampton
*Organon Teknika, 100 Akzo Avenue, Durham,
NC 27712*

Terry C. Crockett
*Laboratory Scientist Supervisor, LA State Dept.
of Health, 325 Loyola Ave., Rm. 709, New
Orleans, LA 70112*

G. David Cross
*Health Scientist, Centers for Disease, Control &
Prevention, 1600 Clifton Rd., N.E., Mailstop G23,
Atlanta, GA 30333*

Norman Crouch Ph.D.
*Minnesota Department of Health, 717 Delaware
Street, S.E., Minneapolis, MN 55440*

Pat Cruse
*Deputy Director, USAF HIV Testing Services,
AL/AOELH 2601 West RD STE 2, Brooks AFB
TX 78235-5241*

Marilou Cruz
*Medical Technologist, Kaiser Medical Group,
22040 Ballinger Street, Chatsworth, CA 41311*

Terry Cummings
*Laboratory Supervisor, Alpha Therapeutic
Corporation, 5700 Pleasant View Road,
Memphis, TN 28134-6503*

Barbara Daanen
*Asst. Scientist, Abbott Laboratories, One Abbott
Park Road, Abbott Park, IL 60064*

Linda Davis
*Medical Technologist, Fort Wayne Regional
Laboratories, 328 Ley Road, Fort Wayne,
Indiana 46825*

Phill Davis
*Sanofi Diagnostics Pasteur, 1000 Lake Hazeltine
Drive, Chaska, MN 55318*

Elizabeth M. Dax M.D.

*National HIV Reference Laboratory, Australia,
Fairfield Hospital, Fairfield 3078, Melbourne, VK
Australia*

Stephen P. Day Ph.D.

*Chief, Molecular Biology, Wisconsin State
Laboratory of Hygiene, 465 Henry Mall, Madison,
WI 53706*

Gloria Echeverria De Perez M.D.

*Institute of Immunology, Caracas, Venezuela,
Apartado 50109, Caracas, OF 1050A Venezuela*

Stephen R. Delaney Ph.D.

*Abbott Laboratories, One Abbott Park Rd., Bldg.
AP-8B, Dept. 09YH, Abbott Park, IL*

Susanne Desrosiers

*Laboratory Scientist, New Hampshire Public
Health Laboratory, 6 Hazen Drive, Concord, NH
03301*

Mark Destree

*Blood Center of S.E. Wisconsin, 4865 S. Katelyn
Circle, #104, Greenfield, WI 53220*

Patti Dewey

*Organon Teknika, 100 Akzo Avenue, Durham,
NC*

Arthur F. DiSalvo M.D.

*Director, Nevada State Health Laboratory, 1660
N. Virginia Street, Reno, Nevada 89503*

Roger Dodd Ph.D.

*Head, Transmissible Diseases Department,
American Red Cross, Holland Laboratory, 15601
Crabbs Branch Way, Rockville, MD 20855*

P. David Dotson, Jr.

*Chief Virology/Immunology, Indiana State
Department of Health, 1330 W. Michigan St.,
Indianapolis, IN 46206-1964*

James Douglas

*Sanofi Diagnostics Pasteur, 1000 Lake Hazeltine
Drive, Chaska, MN 55318*

Harold Dowda Ph.D.

*Director, Bureau of Laboratories, South Carolina
Department of Health, 8231 Parklane Road,
Columbia, SC 29223*

Evelyn Edwards

*Medical Technologist, South Carolina Depart-
ment of Health & Environmental Control Labora-
tory, 8231 Parklane Road, Columbia, SC 29223*

Richard Egan

*Senior Director of Development, Direct Access
Diagnostics, 440 Rt. 22 East, Bridgewater, NJ
08807*

Jim Ellerdock

*Roche Diagnostic Systems, 1080 U.S. Highway
202, Branchburg, NJ 08876*

Robert Falcon

*Asst. Scientist, Abbott Laboratories, One Abbott
Park Road, Abbott Park, IL 60064*

Dennis V. Ferrero

*Laboratory Director, San Joaquin County, CA,
P.O. Box 2009 1601 East Hazelton Avenue,
Stockton, CA 95201*

John Fitchen

*Epitope, 8505 SW Creekside Place, Beaverton,
OR 97005*

Steve Fitzwilliam

*Roche Diagnostic Systems, 1080 U.S. Highway
202, Branchburg, NJ 08876*

Colleen M. Flood

*Senior Bacteriologist, New York State Dept. of
Health, WCL&R/David Axelrod Institute for Public
Health, Albany, NY 12201*

Dr. Bagher Forghani

*Research Scientist, VRDL, CA Dept. of Health
Services, 2151 Berkeley Way, Berkeley, CA
94704*

Diane P. Francis

*Program Administrator, Lab Assurance Program,
Grad. Sch. of Public Health, San Diego State
Univ., 5403 Alpine Blvd., Alpine, CA 91901-2315*

Jack W. Frankel

*Director, Tampa Branch Laboratory, Florida,
3952 W Martin Luther King, Jr. Blvd., Tampa, FL
33614-8404*

Elizabeth A. Franko Dr. P.H.

*Acting Director, Georgia Public Health Labora-
tory, 47 Trinity Ave., S.W. Room 13-H, Atlanta,
GA 30334*

Dwight E. Frazier
Director, Miami Branch Laboratory Florida, HRS,
State of Florida, 1325 NW 14 Avenue, Miami, FL
33125

LaRonda Frazier
Medical Technologist, Kaiser Medical Group,
7027 Alvern Street, #115, Westchester, CA
90045

Sarah A. Fuller
Dept of Diagnostic Retrovirology, Walter Reed
Army Institute of Research, 13 Taft Court,
Rockville, MD 20850

J.L. Gallarda
Senior Research Biochemist, Abbott Laborato-
ries, One Abbott Park Road, Abbott Park, IL
60064

Rick Galli
Chief Tech, HIV Lab., Ontario Ministry of Health,
Ontario Ministry of Health, 81 Resources Rd,
Etobicoke, Ontario Canada M9P 3T1

Dana Gallo
Microbiologist, CA. State Dept. Health Services,
2151 Berkeley Way, Berkeley, CA 94704

J. Richard George Ph.D.
Chief, Dev. Technology Section, DHA, Centers
for Disease Control & Prevention, 1600 Clifton
Road, Atlanta, GA MSD12, Atlanta, GA 30333

Jane P. Gatchell, Dr. P.H.
Associate Director, University Hygienic Labora-
tory, 102 Oakdale Campus #101 OH, Iowa City,
IA 52242-5002

Marcia Goldfarb
Lab Director, Anatek-EP, 17 Bishop St., Portland,
ME 04103

Andrew Goldstein
Epitope, 8505 SW Creekside Place, Beaverton,
OR 97005

Loretta Goodwin
Product Manager, Murex Diagnostics, Inc., 3075
Northwoods Circle, Norcross, GA 30071

Michael Grant
Product Develop. Mgr, Saliva Diagnostic
Systems, 11719 N.E. 95th St., Vancouver, WA
98682

Rodger Gunderson
Coulter Corporation, P.O. Box 169015, Miami, FL

Steven Gutman M.D., M.B.A.
Director, Clinical Laboratory Services Div., Food
and Drug Administration, 1390 Piccard Dr., Mail
Code HFZ-440, Rm. 150L, Rockville, MD 20850

Kenneth Hadlock Ph.D.
Scientist II, Genelabs Incorporated, 505 Penob-
scoe Dr., Redwood City, CA 94063

Nancy J. Haley Ph.D.
Director, Metlife Insurance Co., One Madison
Ave., New York, NY 10010

Larry Hambleton
Sanofi Diagnostics Pasteur, 1000 Lake Hazeltine
Drive, Chaska, MN 55318

W. Harry Hannon Ph.D.
Chief, Clinical Biochem Branch, Centers for
Disease Control & Prevention, 4770 Buford
Highway NE (MS-F19), Chamblee, GA 30341-
3724

William J. Hausler, Jr., Ph.D.
Director, University Hygienic Lab, Univ. of Iowa,
102 Oakdale Campus #101OH, Iowa City, IA
52242-5002

Dr. Patrick Hays
Senior Scientist, KS Health & Environment
Laboratory, Forbes Building, 740, Topeka, KS
66620

Diane Hedger
Murex Diagnostics, Inc., 3075 Northwoods Circle
Norcross, Georgia 30071

Sharon Henderson
Immunology/Virology Supervisor, Community Bld
Center Kansas City, MO, 4040 Main, Kansas
City, MO 64111

Denis R. Henrard Ph.D.
Abbott Laboratories, Dept. 9GJ, Bldg. AP8B One
Abbott Park Road, Abbott Park, IL 60064

Cheryl Hermerath
Manager Serology/Virology, Arizona State
Laboratory Services, 1520 W. Adams Street,
Phoenix, AZ 85007

Sandra Gonzalez Hernandez

Senior Medical Technician, University of Miami,
1611 NW 12 Ave., JMH/East Tower Rm #2044,
Miami, FL 33136

Sue Hocker

Epitope, 8505 SW Creekside Place, Beaverton,
OR 97005

Gerald Hoff, Ph.D.

Epidemiologist, City of Kansas City, Missouri
Health Department, 1423 E. Linwood Blvd.
Kansas City, Missouri 64109

Lindsay F. Hofman Ph.D.

Laboratory Director, Saliva Diagnostic Systems,
11719 N.E. 95th St., Vancouver, Washington
98682

Barbara Hosein Ph.D.

Director, Diagnostic Research & Development,
United Biomedical, Inc., 25 Davids Drive,
Hauppauge, NY 11788

Tom Houston

Lab Technologist, Blood Center of S.E. Wisconsin,
4865 S. Katelyn Cir. #104, Greenfield, WI
53220

Kevin Huttman

Abbott Diagnostics, Dept. 2TN/AP6C, Abbott
Park, IL 60064

Jay Hyman

Research Scientist, Organon Teknika, 100 Akzo
Blvd., Durham, NC 27712

Sandra Irons

Supervisor Medical Microbiology, Nebraska
State Health Laboratory, 3701 S. 14th Street,
Lincoln, Nebraska

Jong-Ho Jean Ph.D.

Virologist, Delaware Public Health Laboratories,
30 Sunyside Road, P.O. Box 1047, Smyrna, DE
19977-1047

Joan Johnson

Abbott Laboratories, 1 Abbott Park Road, Dept.
93E AP10, Abbott Park, IL 60064

Wanda K. Jones

Assistant Director for Science, Office of HIV/
AIDS, Centers for Disease Control & Prevention,
1600 Clifton Rd NE D-21, Atlanta, GA 30033

Laurie Jones

Center Director, Technical Services, Florida
Blood Services, 445 31st Street North, St.
Petersburg, FL 33713

Stephen L. Josephson Ph.D.

Director, Clinical Microbiology & Virology, Rhode
Island Hospital & Brown University, APC 1136,
Rhode Island Hospital, 593 Eddy St., Providence,
RI 02903

Jonathan Kaplan Ph.D.

Asst to the Dir. for Infectious Diseases, Centers
for Disease Control & Prevention, 1600 Clifton
Road., (Mailstop G29), Atlanta, GA 30333

William J. Kassler MD, MPH

Medical Epidemiologist, Centers for Disease
Control & Prevention, 1600 Clifton Road
Mailstop EO2/Div. of STD/HIV Prevention,
Atlanta, GA 30333

Y. Glenn Kataoka

Assistant Laboratory Director, Colorado Dept. of
Health, 4210 E. 11th Avenue, Denver, CO 80220

John W.D. Kay, Ph.D.

Program Director, HIV Organon Teknika
Corporation, 100 Akzo Avenue, Durham, NC
27712

Rowena Kemp

Senior Technologist, Metlife Laboratories, 4
Westchester Plaza, Elmsford, NY 10523

Howard I. Kim

Technical Director, Damon Reference Laboratories,
1011 Rancho Canejo Blvd., Newbury Park,
CA 91320

Renate F. Klein

Director, Pathology, Cornell Medical School,
1300 York Avenue, New York, NY 10021

Glenn Y. Kobayashi

Microbiologist, Hawaii State Dept. of Health,
1250 Punchbowl Street, Honolulu, Hawaii 96813

Jerry Kudlac

Director, Microbiology, Okla. State Dept. of
Health, P.O. Box 24106, Okla. City, OK 73124-
0106

Donald Kwalick M.D.

State Health Officer, Nevada Department of
Human Resources

Mariano F. La Via M.D.
Medical University of South Carolina, 171 Ashley Ave., Charleston, SC 29425

James R. Lane
Project Director, SRA Technologies, 13 Taft Court, Rockville, MD 20850

Pat Langsdale
Vice President, Sales and Marketing, Viral Testing Systems, Inc., 600 Travis, Suite 6980, Houston, TX 77002-3005

Helen Lee Ph.D.
General Manager, Probe Diagnostic Unit, Abbott Laboratories, One Abbott Park Road, Abbott Park, IL 60064-3500

Stephanie Lee-Thomas
Microbiologist, Centers for Disease Control & Prevention, 1600 Clifton Road, MS-D12, Atlanta, GA 30333

Sadie Lehr
Microbiologist, Center for Public Health Laboratories, Oregon Health Division, 1717 SW 10th Ave., Portland, OR

Brian Louie
Senior Microbiologist, San Francisco Dept. of Public Health, 1396 S. Mayfair Avenue, Daly City, CA 94015

Dawn Madigan
Viral Testing Systems, Inc., 600 Travis, Suite 6980, Houston, TX 77002-3005

Fahmy A. Malak M.D.
Medical Consultant, Arkansas Dept. of Health, Public Health Laboratory, 4815 West Markham Street, Little Rock, AR 72205

Pamela Markwardt-Elmer
Microbiologist Senior, Wisconsin State Laboratory of Hygiene, 465 Henry Mall, Rm. 424, Madison, WI 53705

Jay R. Marshall MT(ASCP)
Reference Laboratory Manager, Cambridge Biotech Corporation, One Biotech Park, 365 Plantation Street, Worcester, MA 01605

Allyson May
Epitope, 8505 SW Creekside Place, Beaverton, OR 97005

Vincent C. Marsiglia DLM
Laboratory Administrator, Baltimore City Health Department, BDC Laboratory Rm. 237 1515 W. North Avenue, Baltimore, MD 21217

Robert Myers Ph.D.
Laboratory Scientist, Maryland Department of Health, P.O. Box 2355, Baltimore, MD 21203

Patsy McCarty MT(ASCP)
Division Director I, Mississippi Public Health Laboratory, 2423 North State St., Jackson, MS 39216

Jean McClure
Organon Tekrika, 100 Akzo Avenue, Durham, NC 27712

J. Todd McPherson
Chief, Virology Section, North Carolina State Lab. of Pub. Health, 306 North Wilmington Street, Raleigh, NC 27609

Pat Meisner
T Cell Diagnostics, Inc., 38 Sidney Street, Cambridge, MA 02139

Jeffrey N. Meshulam
Executive Vice President, Cellular Products, Inc., 872 Main Street, Buffalo, NY 14202

Frank J. Michalski Ph.D.
Director Diagnostic Virology, METPATH, 1 Malcolm Ave., Teterboro, NJ 07608

Paul A. Mied Ph.D.
Acting Director, DTTD, Food & Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448

William S. Miller Ph.D.
William S. Miller, Inc., Consultant, 5618 St Albans Way, Baltimore, MD 21212

Daniel C. Mills Ph.D.
Area Resource Director, National Laboratory Training Network, ASTPHLD, 2151 Berkeley Way, Room 803, Berkeley, California 94704

Ofelia Monzón M.D.
Consultant, AIDS Research Group, Research Institute for Tropical Medicine, Manila, Philippines

- Richard C. Moody**
Director, Serology Division, Alabama Dept. of Public Health, Bureau of Clinical Laboratories, 8140 University Dr. Montgomery, Alabama 36130-3017
- Sallie Moore**
Immunology Supervisor, Siena Nevada Labs, 888 Willow St., Reno, NV 89502
- Romulo Morales**
Virology Unit Manager, Georgia Public Health Laboratory, 47 Trinty Ave., S.W. Rm. 139-H, Atlanta, GA 30334
- Ray Morrill**
T Cell Diagnostics, Inc., 38 Sidney Street, Cambridge, MA 02139
- Susan Mottice Ph.D.**
Director, Bureau of Microbiology, Utah Division of Laboratory Services, 46 North Medical Drive, Salt Lake City, Utah 84113-1105
- C. Roy Moulton**
Virus Section Manager, State of Idaho, 2220 Old Pen. Road, Boise, ID 83712
- Geoffrey H. Moyer M.D.**
Medical Director, Damon Reference Laboratories, 1011 Rancho Conejo Blvd., Newbury Park, CA 91320
- Hermann Mucke Ph.D.**
Senior VP of Research and Development, Waldheim Pharmazeutika R&D Laboratory, Viral Testing Systems Corp., 600 Travis, Suite 4750, Houston, Texas 77002
- Darrell Muller**
Roche Diagnostic Systems, 1080 U.S. Highway 202, Branchburg, NJ 08876
- Kate Mulligan**
Becton Dickinson Immunocytometry Systems, 2350 Qume Drive, San Jose, CA 95131
- Michael Neal**
Bacteriologist, New York State Dept. of Health, Wadsworth Ctr for Labs & Research/David Axelrod Institute, Albany, NY 12201
- Lawrence W. Nelson**
Technical Support Supervisor, Nevada State Health Laboratory, 1660 N. Virginia St., Reno, NV 89503
- Sherian Nestor**
Microbiologist, WV Dept of Health & Human Resource, 157 11th Avenue, Office of Laboratory Services, South Charleston, WV 25303
- Richard H. Newhouse Ph.D.**
VP Research, Clinical Studies, Serologicals, Inc., 780 Park North Boulevard, #120, Clarkston, GA 30021
- Janet K.A. Nicholson Ph.D.**
Center for Disease Control and Prevention, National Center for Infectious Diseases, MS-A25, 1600 Clifton Rd., N.E., Atlanta, GA 30333
- Patricia Nix**
Director, Laboratory Services, Alpha Therapeutic Corporation, 5700 Pleasant View Road, Memphis, Tennessee 38134-6503
- Naziha Nuwayhid**
Associate Director, VA Medical Center, 1400 Wallace Blvd., Amarillo, TX 79106
- Thomas A. O'Brien Ph.D.**
Product Director, Retroviral Products & Hepatitis B, Ortho Diagnostic Systems, Inc., 1001 US Hwy 202, P.O. Box 350, Raritan, NJ 08869-0606
- Terri Ozegovich**
Sanofi Diagnostics Pasteur, 1000 Lake Hazeltine Drive, Chaska, MN 55318
- Dr. William Pagels**
Assoc. Director of Development, Direct Access Diagnostics, 440 Rt. 22 East, Bridgewater, NJ 08807
- Mahen Park Ph.D.**
Director, Disease Control Labs., Ind. State Dept. of Health, 1330 W. Michigan St., Indianapolis, Indiana 46206
- Dr. John V. Parry**
PHLS Virus Preference Division, Central Public Health Laboratory, London, 61 Colindale Avenue, London, United Kingdom NW9 5HT
- Peter Parsons**
Manager of Laboratory Integration, Class Development, 1018 Land's End Way, Virginia Beach, VA 23451
- James L. Pearson Dr.P.H.**
Director, Virginia Consolidated Lab Services, One North 14th Street, Room 234, Richmond, VA 23219

Chris Peter Ph.D.

Chief, Public Health Laboratory, San Diego County Public Health Laboratory, 3851 Rosecrans St., P.O. Box 85222, San Diego, CA 92186-5222

Bruce H. Phelps

Mgr. Retrovirus R&D, Abbott Laboratories, One Abbott Park Road, D-93E AP10, Abbott Park, IL 60064-3500

Susan K. Phillips

Microbiologist, Centers for Disease Control and Prevention, 1600 Clifton Road NE Bldg-Room 2250, Atlanta, GA 30330

Mary M. Pollock

Microbiologist, VA Dept. of Health, One N. 14th Street, Richmond, VA 23219

Sylvia Posso

Viral Testing Systems Inc., 600 Travis, Suite 6980, Houston, TX 77002-3005

Sunny Powell

Coulter Corporation, P.O. Box 169015, Miami, FL

Richard A. Quattrocchi

President, Anonymous Test Services, Inc., 2550 W. Golf Road Suite 106, Rolling Meadows, IL 60008-4051

Steven Raia

Boston Biomedica, Inc., 375 W Street, W. Bridgewater, MA 02379

Michael T. Ramirez

Public Health Microbiologist, University (Iowa) Hygienic Laboratory, 102 Oakdale Campus #101 OH, Iowa City, IA 52242-5002

Barry Reed M.D.

V.P. Medical Underwriting, MetLife Insurance Co., One Madison Ave., New York, NY 10010

Andra Reneau

Viral Testing Systems Corporation, 600 Travis Suite 6980, Houston, TX 77002-3005

Lori Rhodes

Becton Dickinson Immunocytometry Systems, 2350 Qume Drive, San Jose, CA 95131

Donald G. Ritter

Microbiologist, State Virology Laboratory, Alaska, P.O. Box 60516, Fairbanks, AK 99706-0516

Claudia Rogers MT (ASCP)

Medical Technologist, Wyoming Public Health Laboratory, 517 Hathaway Bldg., Cheyenne, WY

Rosanna Rumbough

Serology Branch Head, N.C. State Laboratory of Public Health, 306 N. Wilmington St., Raleigh, NC 27609

Jeff J. Runyon

Supervisor, Quality Assurance, Abbott Laboratories, One Abbott Park Road, Abbott Park, IL 60064

Christine Vogel Sapan Ph.D.

Director of Scientific Affairs, North American Biologicals, Inc. (NABI), 16500 N.W. 15 Avenue, Miami, FL 33169

Bob Sass

Zynaxis, Inc., 371 Phoenixville Pike, Malvern, PA 19355

Keith Sayre

Product Manager, Worldwide Commercial Development, Ortho Diagnostic Systems, Inc., 1001 US Hwy 202, P.O. Box 350, Raritan, NJ 08869-0606

Charles Schabel, M.S.

Chief, Serology Section, Div. of HIV/AIDS, Centers for Disease Control and Prevention, 1600 Clifton Road, N.E. D12, Atlanta, GA 30333

William Schalla M.S.

Chief, Model Performance Evaluation Program, Centers for Disease Control and Prevention, 1600 Clifton Road, N.E., Mail Stop G23, Atlanta, GA 30333

John Schilling

Sanofi Diagnostics Pasteur, 1000 Lake Hazeltine Drive, Caska, MN 55318

Carol M. Schimek

Transfusion Transmitted Virus, Mayo Clinic, 200 First Street, S.W., Rochester, MN 55905

Nancy Schneider

Organon Teknika, 100 Akzo Avenue, Durham, NC 27712

Richard Schumacher

Boston Biomedica, Inc., 375 W. Street, W. Bridgewater, MA 02379

Mark Schwerzler
Chemist, TSRI, 305 South Street, Boston, MA 02130

Betsy R. Sears
Lab Manager, Osborn Laboratories, 14901 W. 117th St., Olathe, KS 66062

Eugene Seymour M.D., M.P.H.
CEO, Saliva Diagnostic Systems, 11719 N.E. 95th St., Vancouver, WA 98682

S.I. Shahied Ph.D.
Assistant Commissioner, NJ Division of Public Health NJ State Department of Health, CN360, Trenton, NJ 08625

Jacqueline M. Sheffield
Supervisory Medical Technologist, Infectious Diseases Division, 8901 Wisconsin Avenue, Bldg. 9 Room 1637, Bethesda, MD 20889-5600

Haynes W. Sheppard, Ph.D.
Research Scientist III, VRDL, Calif. Dept. of Health Services, 2157 Berkeley Way, CA

Ken Shockley
Murex Diagnostics, Inc., 3075 Northwoods Circle, Norcross, GA 30071

William Skillman
Product Director, Retrovirology, Ortho Diagnostic Systems, Inc., 1001 US Hwy 202, P.O. Box 350, Raritan, Raritan, NJ 08869-0606

J. Donnell Small, Jr.
Manager, Immunodiagnostics, Organon Teknika Corporation, 100 Akzo Avenue, Durham, North Carolina 27712

Thomas F. Smith Ph.D.
Chair Clinical Microbiology, Mayo Clinic, 200 1st Street, S.W., Rochester, MN 55905

Edith S. H. Smith
Supervisory Health Science Specialist, Naval Central HIV Program, 8901 Wisconsin Avenue, P.O. Box 658, Bethesda, Maryland 20889-5600

Apryl Smith
Lab Technologist, Blood Center of S.E. Wisconsin, 5218 N. Lovers Lane Road #1, Milwaukee, WI 53225

Janet Sowka
Manager, South Bend Medical Foundation, 530 N. Lafayette Blvd., South Bend, IN 46617

John F. Stephens
Abbott Laboratories, 1 Abbott Park Road, Abbott Park, IL 60064

Susan Stramer Ph.D.
Section Manager, Retrovirus Research and Development, Abbott Laboratories, D93E, AP10, Abbott Park, IL 60064

Henry L. Strother
Public Health Labor. Scientist, Missouri State Public Health Laboratory, 307 West McCarty St., Jefferson City, MO 65101

Terre Sutherland
Lab Director, Community Bio-Resources, Inc., 1618 3rd Avenue N, Birmingham, AL 35203

Janet Tegtmeyer
Director, Processing Lab, Sacramento, CA Blood Center, 1625 Stockton Blvd., Sacramento, CA 95816

Ralph Timperi
Assistant Commissioner, State Laboratory Institute, Massachusetts, 305 South Street, Jamaica Plain, MA 02130

Chris Tornstrom
Zynaxis, Inc., 371 Phoenixville Pike, Malvern, PA 19355

Margaret Turano
T Cell Diagnostics, Inc., 38 Sidney Street, Cambridge, MA 02139

Ronald Turnicky D.O., LTC, MC
Diagnostic Retrovirology, Walter Reed Army Institute, Rockville, MD 20850

Howard Urnovitz Ph.D.
Founder & CSO, Calypte Biomedical, 1440 Fourth Street, Berkeley, CA 94710

Carol Valstyn
Becton Dickinson Immunocytometry Systems, 2350 Qume Drive, San Jose, CA 95131

Beth Vela
Supervisor, Quality Assurance, Abbott Laboratories, One Abbott Park Road, Abbott Park, IL 60064

Richard Walkenbach
Public Health Laboratory Scientist, Missouri State Public Health Laboratory, 307 West McCarty Street, Jefferson City, MO 65101

Diane Wara M.D.

Professor, Department of Pediatrics, Moffitt Hospital School of Medicine, University of California, San Francisco, California

Erik M. Werschauer Ph.D., MT

Supervisor, Clinical Reference Laboratory, Genetic Systems Corp., 6565 165th Avenue, N.E., Redmond, WA 98052

Barbara Welblen

Boston Biomedica, Inc., 375 W. Street, W. Bridgewater, MA 02379

Barbara Werner Ph.D.

Director, Virology/ Clin. Invest. Division, Massachusetts State Laboratory Institute, Department of Public Health, 305 South Street, Jamaica Plain, MA 02130

Judith Wethers MS

Director of Testing Retrovirology Laboratory, New York Department of Health, New York Department of Health, Box 509, Albany, NY 12201

Roxanne Whitesides

Immunohematology Supervisor, Kaiser Permanente, 16601 E Centre Tech Parkway, Aurora, CO 80011

Judith Wilber Ph.D.

Associate Director, Nucleic Acid Systems, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608

Bill Wong

Zynaxis, Inc., 371 Phoenixville Pike, Malvern, PA 19355

Jolene Wong-Lee

Product Manager, Diagnostics, Genelabs Diagnostics, USA, 505 Penobscot Drive, Redwood City, CA 94063

Norm Woods

Sanoil Diagnostics Pasteur, 1000 Lake Hazeltine Drive, Chaska, MN 55318

Hou Xinyue

Denver Disease Control Service, 605 Bannock Street, Denver, CO 80204

Raphael J. Yankey

Supervisor/Serology Lab, George Washington Univ. Med. Ctr., 901 23rd Street, N.W., Room 5353N, Washington, DC 20037

JoAnn Yee

Supervisor, Univ. of Calif. AIDS Virus Lab, Dept. of Medical Pathology, Davis, CA 95616

Elaine Yeh

Public Health Microbiologist, State of Calif. Virus Lab, CA Dept. of Health Services, 2151 Berkeley Way, Berkeley, CA 94704

Belinda Yen-Lieberman Ph.D.

Staff Scientist, Cleveland Clinic Foundation, Cleveland Clinic Fdn., Dept. of Clinical Path. L40, Cleveland, OH 44195-5140

Marc W. Yonker

Microbiologist, Indiana State Department of Health, 1330 West Michigan, Indianapolis, IN 46202

Sue Yoshino

Supervising Pub. Health Microbiologist, Public Health Laboratory, County of Orange, CA, 1729 W. 17th Street, Santa Ana, CA 92706

Judy Yost M.A. MT(ASCP)

Medical Technician Advisor, Bureau Director, HCFA, 6325 Security Blvd., 202 Meadows East Building, Baltimore, MD 21207

Madonna Young

Unit Supervisor, Serology Dept, Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA 92690-6130

Susan Yu

Medical Technologist, Navy Central HIV Program, 12914 Autumn Dr., Silver Spring, MD 20904-3335

Susanne Zanto

Virology Supervisor, Montana Public Health, Laboratory, Cogswell Building, Helena, MT 59620

Minas Zartarian

Senior Specialist, University of California, Irvine, Medical Center, 101 The City Drive, Orange, CA 92668

Wojciech M. Zawada M.D., Ph.D.

Director, Immuno-Chemistry Section, Arkansas Dept. of Health, Division of Public Health Laboratories, 4815 W. Markham Street - Slot #47, Little Rock, AR 72205-3867